Tarsus Pharmaceuticals Inc

NASDAQ:TARS   4:00:00 PM EDT
16.69
-0.24 (-1.42%)
4:02:15 PM EDT: $16.69 0.00 (0.00%)
Earnings Announcements

Tarsus Reports Third Quarter 2022 Financial Results

Published: 11/09/2022 11:26 GMT
Tarsus Pharmaceuticals Inc (TARS) - Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements.
New Drug Application for Tp-03 Accepted; PDUFA Target Action Date August 25, 2023.
Cash Runway Anticipated Into at Least 2026 for the Planned Commercial Launch of Tp-03 and Continued Pipeline Development.
As of September 30, 2022, Cash, Cash Equivalents and Marketable Securities Were $226.6 Million.
Qtrly Loss per Share $0.84.
Q3 Earnings per Share View $-0.97 -- Refinitiv Ibes Data (analyst estimates).
Further Company Coverage: .
((reuters.
Briefs@thomsonreuters.
Com;)).
Revenue is expected to be $10 Million
Adjusted EPS is expected to be -$0.73

Next Quarter Revenue Guidance is expected to be $5 Million
Next Quarter EPS Guidance is expected to be -$0.94

More details on our Analysts Page.